These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

704 related items for PubMed ID: 31706338

  • 1. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R, Wolfler A, Picone S, Rossi GA, Gualberti G, Merolla R, Del Vecchio A, Villani A, Midulla F, Dotta A.
    Ital J Pediatr; 2019 Nov 09; 45(1):139. PubMed ID: 31706338
    [Abstract] [Full Text] [Related]

  • 2. Neonatal outcomes following new reimbursement limitations on palivizumab in Italy.
    Belleudi V, Trotta F, Pinnarelli L, Davoli M, Addis A.
    Arch Dis Child; 2018 Dec 09; 103(12):1163-1167. PubMed ID: 30217858
    [Abstract] [Full Text] [Related]

  • 3. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
    Priante E, Tavella E, Girardi E, Militello MA, Mardegan V, Maule MM, Dall'Agnola A, Baraldi E, Manzoni P.
    Am J Perinatol; 2019 Jul 09; 36(S 02):S77-S82. PubMed ID: 31238365
    [Abstract] [Full Text] [Related]

  • 4. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
    Rajah B, Sánchez PJ, Garcia-Maurino C, Leber A, Ramilo O, Mejias A.
    J Pediatr; 2017 Feb 09; 181():183-188.e1. PubMed ID: 27855996
    [Abstract] [Full Text] [Related]

  • 5. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD.
    J Manag Care Pharm; 2010 Feb 09; 16(1):15-22. PubMed ID: 20044843
    [Abstract] [Full Text] [Related]

  • 6. The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence.
    Capizzi A, Silvestri M, Orsi A, Cutrera R, Rossi GA, Sacco O.
    Ital J Pediatr; 2017 Aug 14; 43(1):71. PubMed ID: 28807039
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
    Kong AM, Winer IH, Zimmerman NM, Diakun D, Bloomfield A, Gonzales T, Fergie J, Goldstein M, Krilov LR.
    Am J Perinatol; 2023 Oct 14; 40(14):1529-1536. PubMed ID: 34704241
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH.
    Eur J Pediatr; 2003 Apr 14; 162(4):237-44. PubMed ID: 12647196
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA.
    Pediatrics; 1999 Sep 14; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [Abstract] [Full Text] [Related]

  • 16. Respiratory syncytial virus risk factors in late preterm infants.
    Lanari M, Silvestri M, Rossi GA.
    J Matern Fetal Neonatal Med; 2009 Sep 14; 22 Suppl 3():102-7. PubMed ID: 19925369
    [Abstract] [Full Text] [Related]

  • 17. Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants.
    Staebler S, Blake S.
    Policy Polit Nurs Pract; 2021 Feb 14; 22(1):41-50. PubMed ID: 33050785
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus.
    Blake SM, Tanaka D, Bendz LM, Staebler S, Brandon D.
    Adv Neonatal Care; 2017 Aug 14; 17(4):292-298. PubMed ID: 27926583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.